NRF1 and cancer: Modulating Nrf1 function via fine-tuning N-glycosylation could also be exploited therapeutically, as blocking Nrf1 processing has been proposed as a strategy to enhance the efficacy of proteasome inhibitor drugs, such as BTZ, in cancer treatment [18,29].